Global Targeted Drug ALK Inhibitors for NSCLC Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Targeted Drug ALK Inhibitors for NSCLC Market Overview

• 1.1 Product Overview and Scope of Targeted Drug ALK Inhibitors for NSCLC
• 1.2 Classification of Targeted Drug ALK Inhibitors for NSCLC by Types
  • 1.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Types in 2018
  • 1.2.3 Crizotinib
  • 1.2.4 Ceritinib
  • 1.2.5 Alectinib
  • 1.2.6 Brigatinib
  • 1.2.7 Lorlatinib
  • 1.2.8 Other
• 1.3 Global Targeted Drug ALK Inhibitors for NSCLC Market by Application
  • 1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Squamous Cell Carcinoma of NSCLC
  • 1.3.3 Adenocarcinoma of NSCLC
  • 1.3.4 Large Cell Carcinoma of NSCLC
• 1.4 Global Targeted Drug ALK Inhibitors for NSCLC Market by Regions
  • 1.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)
• 1.5 Global Market Size of Targeted Drug ALK Inhibitors for NSCLC (2014-2024)

2 Manufacturers Profiles

• 2.1 Pfizer
  • 2.1.1 Business Overview
  • 2.1.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Novartis
  • 2.2.1 Business Overview
  • 2.2.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
  • 2.3.1 Business Overview
  • 2.3.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 ARIAD Pharmaceuticals (Takeda)
  • 2.4.1 Business Overview
  • 2.4.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Genvio Pharma Limited
  • 2.5.1 Business Overview
  • 2.5.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Beacon Pharma Limited
  • 2.6.1 Business Overview
  • 2.6.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Drug International Limted
  • 2.7.1 Business Overview
  • 2.7.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Incepta Pharmaceuticals
  • 2.8.1 Business Overview
  • 2.8.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

3 Global Targeted Drug ALK Inhibitors for NSCLC Market Competition, by Players

• 3.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Targeted Drug ALK Inhibitors for NSCLC Players Market Share
  • 3.2.2 Top 10 Targeted Drug ALK Inhibitors for NSCLC Players Market Share
• 3.3 Market Competition Trend

4 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Regions

• 4.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Regions
• 4.2 North America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 4.3 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 4.5 South America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

5 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

• 5.1 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)
• 5.2 USA Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 5.3 Canada Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

• 6.1 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)
• 6.2 Germany Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 6.3 UK Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 6.4 France Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 6.5 Russia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 6.6 Italy Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

• 7.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)
• 7.2 China Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 7.3 Japan Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 7.4 Korea Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 7.5 India Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

8 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

• 8.1 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)
• 8.2 Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Targeted Drug ALK Inhibitors for NSCLC by Countries

• 9.1 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 9.3 UAE Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

10 Global Targeted Drug ALK Inhibitors for NSCLC Market Segment by Type

• 10.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Type (2014-2019)
• 10.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Type (2019-2024)
• 10.3 Crizotinib Revenue Growth Rate (2014-2024)
• 10.4 Ceritinib Revenue Growth Rate (2014-2024)
• 10.5 Alectinib Revenue Growth Rate (2014-2024)
• 10.6 Brigatinib Revenue Growth Rate (2014-2024)
• 10.7 Lorlatinib Revenue Growth Rate (2014-2024)
• 10.8 Other Revenue Growth Rate (2014-2024)

11 Global Targeted Drug ALK Inhibitors for NSCLC Market Segment by Application

• 11.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2014-2019)
• 11.2 Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Application (2019-2024)
• 11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
• 11.4 Adenocarcinoma of NSCLC Revenue Growth (2014-2019)
• 11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2014-2019)

12 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast (2019-2024)

• 12.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast (2019-2024)
• 12.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Regions (2019-2024)
• 12.3 North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
• 12.4 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
• 12.6 South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology